Clinical Oncology

[Long-term central venous access devices in oncology]

PAJKOS Gábor

DECEMBER 10, 2016

Clinical Oncology - 2016;3(04)

[Long-term central venous access devices are essential in the management of oncology patients, as they minimize the discomfort caused by frequent venipuncture and cannulation. Indications of application of central venous accesses, possibilities of implantations, immediate and long term complications, they prevention and obviation has been reported based on guidelines and relevant publications. Long term implantable central venous accesses handled by well-trained and exercised team, working with principles of maintenance, these manipulations are effective and safe, therefore suitable in oncological practice.]

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[Foreword]

A szerkesztők

Clinical Oncology

[Reminiscences of a Peer – Remembering Sándor Eckhardt]

KERPEL-FRONIUS Sándor

Clinical Oncology

[News from the World]

Clinical Oncology

[Side-effects of immunotherapy]

LANDHERR László

[The immune system has an important role in controlling and eradicating cancer cells. Antibody therapy against several negative immunologic regulators (checkpoints) has demonstrated promise in a variety of malignancies. The immune checkpoint blockade with antibodies against cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) and its ligand have a unique and distinct pattern of adverse events. Immune-related adverse events are most commonly observed in the skin, gastrointestinal tract, liver and the endocrine system. Early recognition and treatment are believed to be important in mitigating severity of such adverse effects.]

Clinical Oncology

[Chemotherapy of multiple myeloma]

MIKALA Gábor, CEGLÉDI Andrea, CSACSOVSZKI Ottó, SZEMLAKY Zsuzsanna, PETŐ Mónika

[Multiple myeloma is a multifaceted haematological disease, a plasma cell malignancy that may pose an oncological differential diagnostic challenge. The importance of this disease is emphasized by its incidence. Since there are multiple novel therapies available for myeloma patients, decade-long survival in not uncommon; therefore, myeloma patients provide a signifi cant part of the patients referred to hematological clinics. In this review, fi rst the novel diagnostic criteria are introduced, followed by the standard therapeutic approaches for transplant-eligible and ineligible patients. As the disease nearly always relapses, the later line therapies available in this malignancy are presented with a special emphasis on the Hungarian haematological practice.]

All articles in the issue

Related contents

Lege Artis Medicinae

[A modern approach to the surgical treatment of osteoarthritis of the hip]

SZENDRŐI Miklós, SÓLYOM László

[The authors review the development of surgical treatment of osteoarthritis of the hip, including the joint preserving interventions for biomechanical reconstruction in prearthroses, and the joint deceasing, or joint replacing procedures in advanced osteoarthritis. Demonstrating the indications, contraindications and possible complications they point to the responsibility of the surgeon, and to the changes of the recent strategy comparing to the previous one. They give a „state of the art” description regarding the surgical treatment of osteoarthritis of the hip supported by references from the literature and their own experience.]

Hungarian Radiology

[Metal objects in the MR]

VÁRALLYAY György

[During magnetic resonance imaging the patient is exposed to three different types of electromagnetic radiation: static magnetic field, gradient or time varying magnetic fields and radiofrequency electromagnetic fields. The potential risks associated with performing MRI in patients with ferromagnetic implants, materials, or devices are related to the possibility of movement or dislodgement, to the induction of electrical currents and to the heating. The majority of metallic implants are considered to be safe for MRI, but patients with cardiac pacemakers, ferromagnetic aneurysm clips, cochlear implants, implantable drug infusion pumps should not be examined by MRI.]

Lege Artis Medicinae

[The development of insulin treatment from discovery of insulin to analogue preparations]

KÁPLÁR Miklós, PARAGH György

[The discovery of insulin was a milestone in the treatment of diabetes mellitus. Animalderived (porcine and cattle) insulins available at the beginning were later replaced by human insulins. Recently, analogue insulins are the most widespreadly used. Besides the increase in the quantity and improvement in the quality of the insulin products, the growth of the treatment regimes is apparent, as well. That varies from the once-given daily basal insulin treatment added to oral antidiabetic drugs to intensified insulin therapy, administering insulin 4-5 times daily. Considering the benefits proved by previous basic and clinical studies, the authors summarize the most important properties of the commonly used insulin treatment regimes in this review. They also briefly outline the important aspects of the patient-centered personalized therapy and the connection between insulin therapy and carcinogenesis.]

Clinical Neuroscience

[EFFICACY, SAFETY AND EFFECT ON THE QUALITY OF LIFE OF GABAPENTIN IN ADULT EPILEPSY - RESULTS OF A PROSPECTIVE OPEN-LABEL QUASI NATURALISTIC HUNGARIAN MULTICENTER STUDY (PHASE HUMAN-IV).]

RAJNA Péter, SZÍJÁRTÓ Elvira

[Purpose - To evaluate the efficacy and safety of gabapentin (GBP) in idiopathic or crypto/symptomatic partial epilepsy in adults. Methods - We performed a prospective open label add-on study in pharmacoresistant patients with simple or complex partial or generalized seizures of partial onset (at least four seizures per month). GBP was added to no more than two baseline antiepileptics and the efficacy was rated primarily according to the seizure frequency. The secondary efficacy parameters were the change in the seizure severity scores (measured by the NHS3 scale) and in the quailty of life (measured by the QUOLIE-31 questionnaire). GBP was added up to 1500-1600 mg per day in the titration period than an individual optimalization was allowed in any further visits. The follow-up period was three months. Population - Fourteen Hungarian epilepsy out-patient unit participated in the study. 72 patients were enrolled, GBP was applied in 63 persons (ITT population) and 57 completed the study. Results - A more than 50% decrease in seizure frequency was found in more than 70% of the patients in the third month. Among them just every third patient became seizure-free. Significant improvement appeared also in the severity of seizures and in the total score of the quality of life questionnaire. There was no difference either according to the etiology of the epilepsy or the seizure types. GBP was tolerated excellently. There was no need to decrease of the dosage of GBP and the side effects were mild and of transitory nature. Consequences - GBP appears to be a valuable antiepileptic drug considering its high efficacy and extremely favourable tolerance. While GBP also decreases the severity of the seizures, its complex effects result an improvement in the quality of life of the patients. The positive effects have been durable during the follow-up. Open label naturalistic studies of larger population are needed to clear the special indications of GBP in chronic partial epilepsies.]

Clinical Neuroscience

[THE AUGMENTATION OF CLOZAPINE TREATMENT WITH ELECTROCONVULSIVE THERAPY]

GAZDAG Gábor, KOCSIS-FICZERE Nárcisz, TOLNA Judit

[Objectives - The assessment, in terms of safety and efficacy, of augmenting clozapine monotherapy, as well as combined psychopharmacotherapy involving clozapine, with electroconvulsive therapy (ECT). Method - Reviewed were the charts of patients who received clozapine-ECT treatment in the Department of Psychiatry and Psychotherapy of Semmelweis University between November 1999 and December 2003. Results - During the studied period there were altogether 43 patients treated with the combination of clozapine and electroconvulsive therapy. In the schizoaffective group, the values for post-electroconvulsive therapy CGI were significantly lower than either in the catatonic (Z=-3.72, p<0.01) or in the hebephrenic (Z=-3.17, p<0.01) group. Among the groups created on the basis of the number of augmentation strategies utilized, the clozapine+3 group consisted of patients significantly older than the clozapine+1 group (Z=2.45, p=0.01). In the clozapine monotherapy group, the values for post-electroconvulsive therapy CGI were significantly lower than in any of the groups that had received a combination of augmentations (monotherapy-1 augmentation: Z=-3.01, p<0.01; monotherapy-2 augmentation: Z=-2.89, p<0.01; monotherapy- 3 augmentation: Z=-2.41, p=0.01). Conclusions - According to our examinations, the augmentation of clozapine treatment with electroconvulsive therapy should be tried primarily on schizoaffective patients, in case the clozapine monotherapy is ineffective. The simultaneous use of different augmentation strategies is expected to increase only the side effects not the efficacy of the treatment.]